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RNA interferencelatory RNAs that post-transcriptionally regulate gene expression and can be
encoded by viral as well as cellular genomes. The functions of most viral miRNAs are unknown and few have
been studied in an in vivo context. Here we show that the murine polyomavirus (PyV) encodes a precursor
microRNA that is processed into two mature microRNAs, both of which are active at directing the cleavage of
the early PyV mRNAs. Furthermore, we identify a deletion mutant of polyomavirus that is defective in
encoding the microRNAs. This mutant replicates normally and transforms cultured cells with efﬁciencies
comparable to wildtype PyV. The miRNA mutant is competent to establish a transient infection of mice
following parenteral inoculation, and is cleared post infection at approximately the same rate as the wildtype
virus. In addition, under these laboratory conditions, we observe no differences in anti-viral CD8 T cell
responses. These results indicate that PyV miRNA expression is not essential for infection of cultured cells or
experimentally inoculated mice, and raise the possibility that its role in natural infection might involve
aspects of acquisition or spread that are not recapitulated by experimental inoculation.
© 2009 Elsevier Inc. All rights reserved.Introduction
MicroRNAs (miRNAs) are small (approximately 22 nucleotide)
RNA molecules that regulate gene expression (reviewed in (Bartel,
2004; Carthew, 2006; He and Hannon, 2004; Kim, 2005)). MiRNAs are
processed from a longer primary transcript containing a region of
secondary structure that folds into an ∼100–120 nucleotide hairpin
structure. This long hairpin region is recognized and excised by the
nuclear multi-protein microprocessor complex into a 50–70 nucleo-
tide hairpin precursor miRNA (pre-miRNA) (Denli et al., 2004;
Gregory et al., 2004; Seitz and Zamore, 2006). The pre-miRNA is
exported to the cytoplasm and is further processed by the Dicer
endonuclease (Bohnsack et al., 2004; Hutvagner et al., 2001; Ketting
et al., 2001; Lund et al., 2004; Yi et al., 2003), eventually becoming the
mature single-stranded, 22 nucleotide effector molecule bound by the
multiprotein RNA Induced Silencing Complex (RISC) (Kim, 2005).
Typically, only one arm of the pre-miRNA hairpin is favored to be
active within RISC (Matranga et al., 2005). For the most part, RISC-
bound miRNAs bind with imperfect complementarity to the 3′ UTR ofSullivan).
ll rights reserved.a target mRNA. This results in translational repression, probably
throughmultiplemechanisms (Filipowicz et al., 2008). In addition, if a
miRNA has perfect complementarity to an mRNA target, it can guide
RISC to speciﬁcally cleave the mRNA target in UTR as well as non-UTR
regions of the transcript (Doench et al., 2003; Hutvagner and Zamore,
2002; Zeng et al., 2003). This mechanism is analogous to cleavage
mediated by small-interfering RNAs (siRNAs). However, miRNAs that
mediate cleavage in an siRNA-like fashion are rare in animal cells. In
fact, there is only a single mammalian miRNA known to function in
this manner (Mansﬁeld et al., 2004; Yekta et al., 2004). MiRNAs have
generated enormous interest, in part, because they have been impli-
cated as playing regulatory roles in numerous and diverse develop-
mental and cellular processes. Recently, miRNAs encoded by viruses
have been discovered, and increasing evidence suggests that both host
and viral-encoded miRNAs play an important role in viral infection.
Viral-encoded microRNAs have been discovered in several virus
families (reviewed in Cullen, 2006; Grey et al., 2008; Nair and Zavolan,
2006; Pfeffer and Voinnet, 2006; Samols and Renne, 2006; Sarnow
et al., 2006; Sullivan, 2008; Sullivan and Ganem, 2005b). Most viral
miRNAs have been identiﬁed in members of the herpesviral family.
Themacaque and humanpolyomaviruses Simian Virus 40 (SV40), JCV,
and BKV have also been shown to encode miRNAs with shared, partial
sequence identity (Seo et al., 2008; Sullivan et al., 2006; Sullivan et al.,
158 C.S. Sullivan et al. / Virology 387 (2009) 157–1672005). The function of the vast majority of viral miRNAs remains
unknown, but recent progress has beenmade in identifying molecular
targets of several viral miRNAs (Barth et al., 2008; Gottwein et al.,
2007; Grey et al., 2007; Lo et al., 2007; Pfeffer et al., 2004; Samols
et al., 2007; Skalsky et al., 2007; Stern-Ginossar et al., 2007). Viral
miRNAs have been described that target host or viral transcripts, via
either translational repression or through siRNA-like mediated cleav-
age. However, an in depth understanding of the in vivo functions of
viral miRNAs is lacking.
Murine polyomavirus (PyV) was the ﬁrst polyomavirus discovered
(reviewed in Benjamin, 2001). When some strains of newborn mice
are infected in a laboratory setting, PyV induces numerous tumors in
multiple tissue types (Benjamin, 2001; Cole, 1996). As such, PyV has
become a valuable model for understanding the mechanisms of viral-
mediated tumorigenesis. However, despite its oncogenic potential,
PyV establishes an asymptomatic persistent infection under natural
conditions (Carroll et al., 2007). More recently, PyV has been used as a
tool to better understand the host immune response to viral infection
(Benjamin, 2001; Moser and Lukacher, 2001). Studies show that
epitopes from the early proteins, middle T antigen (MT) and large T
antigen (LT) are immunodominant, with most CTLs cloned from in-
fected animals being responsive to MT or LT (Kemball et al., 2005;
Lukacher et al., 1999). Thus, laboratory infection of mice with PyV has
become a valuable model system for virological, immunological, and
tumorigenesis studies.
PyV has a small, approximately 5 kb double-stranded circular DNA
genome. Near the origin of replication (ori) are the early and late
promoters that direct transcription in opposite directions. Through
alternative splicing, three early proteins are encoded: small T antigen
(sT), middle T Antigen (MT) and large T antigen (LT). These multi-
functional proteins are involved in signaling, altering the cell cycle
control mechanisms and promoting viral DNA replication (Cole,1996).
The late transcripts encode three structural protein components of
the capsid: VP1, VP2, and VP3. Despite being separated by ∼100 mil-
lion of years of evolution, SV40 and PyV share extensive similarities in
genomic architecture, transcript patterns, and amino acid identity of
some proteins. Interestingly, PyV RNA structures compatible with a
pre-miRNAwere posited by Treisman in the late 1970s (for review see
Sullivan et al., 2006). These studies (Treisman, 1981; Treisman and
Kamen, 1981) combined with the need to develop an in vivomodel to
study the functions of viral miRNAs, led us to examine whether PyV
encodes miRNAs.
We have previously shown that SV40 encodes a pre-miRNA
(SVpre-miRNA) that is processed into two miRNAs, which function
to downregulate early protein levels (Sullivan et al., 2005). Further-
more, a mutant SV40 virus that fails to make the pre-miRNA is more
sensitive to cytotoxic T cell (CTL) lysis in in vitro assays. These data
led to the suggestion that the SV miRNAs may augment evasion of the
immune response during infection in vivo (Sullivan et al., 2006;
Sullivan et al., 2005). Here we show that PyV encodes a pre-miRNA
late during infection that is processed into two stable miRNAs, and
explore the functions of these miRNAs both in culture and experi-
mental inoculation of mice.
Results
Identiﬁcation of PyV miRNAs
We set out to determine whether PyV, which is a well-
characterized animal model of polyomavirus infection, encodes
miRNAs. First we compared the sequence of the PyV genome to
SV40 to look for sequence similarity to the SVpre-miRNA. On the
whole, the genomic architecture of PyV and SV40 are similar, how-
ever, the region of SV40 that encodes the pre-miRNA is not conserved
in PyV. Furthermore, no other region of the PyV genome contains
signiﬁcant nucleotide similarity with the SV40 pre-miRNA (data notshown). We next asked whether PyV might encode a pre-miRNA that
is not homologous to the SVpre-miRNA. We applied Vmir (Grundhoff
et al., 2006; Sullivan and Grundhoff, 2007; Sullivan et al., 2005), a
pre-miRNA prediction algorithm, to the PyV genome. Two top scoring
candidates (MF1 and MR1 for microRNA forward and reverse
orientation) scored above an arbitrary cut off score of 200 (Fig. 1A)
and were further pursued. Candidate MR1 has a predicted long
hairpin stem and stable secondary structure (Fig. 1B) and maps in the
late orientation approximately 1700 nucleotides downstream from
the late polyadenylation site, complementary to the early RNAs
(Fig. 1C). Neither MF1 nor MR1 has any sequence identity in common
with the SV40 pre-miRNA, and both map to a different genomic
location. However, because of its location and orientation, MR1 still
could potentially generate miRNAs that downregulate early transcript
levels.
To test the validity of our computational predictions, we designed
probes to both the 5 prime (5p) and three prime (3p) arms of each
candidate and conducted Northern blot analysis. We did not detect
any speciﬁc signal with probes directed against MF1 (data not
shown), however, distinct bands migrating around 22 nucleotides
(the typical size of a miRNA) and ∼65 nucleotides (the typical size of
the pre-miRNA) were detected with probes directed against either
the 5p or 3p arms of the MR1 candidate (Fig. 2). A control probe
designed to hybridize to the loop portion of the pre-miRNA (Terminal
loop probe) did not recognize any signal migrating at 22 nucleotides
but readily detected the ∼65 nucleotide pre-miRNA. This demon-
strates that there is not general degradation of transcripts in this
region of the genome that could account for the∼22 nucleotide bands
we detect with the 5p and 3p probes. Next we determined the
kinetics of pre-miRNA/miRNA expression. We observed bands
corresponding in size to both the pre-miRNA and miRNA that are
readily detectable starting around 28 h.p.i. (Fig. 2B). Expression of
these bands continued throughout the duration of the experiment.
Combined, these results strongly suggest that we have identiﬁed a
novel, late-expressed PyV pre-miRNA that is processed into two
different miRNAs. Notably, the 5p and 3p miRNAs are both readily
detectable and the pre-miRNA is present at higher amounts than the
processed miRNAs. These are atypical but not unprecedented features
of some pre-miRNA/miRNA derivatives.
PyV miRNAs direct cleavage of the early RNAs
Both miRNAs we identiﬁed have perfect complementarity to the
early RNA transcripts. Therefore, we tested the hypothesis that these
miRNAs might direct cleavage of the early transcripts in a manner
analogous to siRNA-mediated cleavage. In 1984, Fenton and Basillico
identiﬁed an unexplained early transcript (Fenton and Basilico,
1982). Through Northern blot analysis, they identiﬁed an abundant
early transcript migrating at approximately ∼1800 nucleotides in
length. It is notable that the transcript they identiﬁed is robustly
present only at late times of infection, despite being of early
orientation. Furthermore, they showed that this transcript is not
capped. This is exactly the size range and 5′ end structure we would
predict should exist if the PyV miRNAs we have identiﬁed are
directing cleavage of the early transcripts. To map the early
transcripts withmore precision, we performed Northern blot analysis
on polyadenylated-enriched RNAs using probes that recognize the
early RNAs just proximal to the predicted miRNA cleavage sites on
either the 5′ and 3′ ends (Figs. 3A and B). When probing with the 5′
probe, that should recognize only the full length mRNAs, we detect a
doublet consistent with the multiple isoforms of the early mRNAs
present during infection (Fenton and Basilico, 1982) (Fig. 3B, left
panel). However, when probing with the 3′ probe, that should
recognize both the full length mRNAs and the predicted cleavage
fragments, we observe a faster migrating band consistent with the
uncapped transcript ﬁrst reported by Fenton and Basillico (Fenton
Fig. 1. Prediction of a PyV pre-miRNA. (A) Vmir was used to predict candidate pre-miRNAs in the PyV genome (shown is a Vmir prediction plot with a cutoff score of 115). Top, The
vertical axis indicates Vmir score, the horizontal axis indicates nucleotide position. The squares show individual candidates in the early (forward) orientation and triangles indicate
candidates in the late (reverse) orientation. The top-scoring late orientation candidate, MR1 (formicroRNA reverse 1) is circled in red. Bottom, is a linearizedmap of the PyV genome,
corresponding to the nucleotide positions depicted in the Vmir plot. (B) Secondary structure prediction of candidate MR1 as called by Vmir. The red nucleotides correspond to the
estimated position of the 5p miRNA, the blue nucleotides correspond to the estimated position of the 3p miRNA. (C) Genomic organization of PyV. The early (light blue) and late
(orange) transcripts are indicated. Promoters are indicated with arrowheads. Locations of the 3p and 5p miRNAs (derived from the MR1 candidate pre-miRNA are shown, blue and
red arrowheads, respectively).
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Fig. 2. Northern blot conﬁrmation of MR1 candidate. (A) Northern blot analysis was conducted using the probes diagramed in red (left side of Fig.) on RNA harvested from mock or
PyV-infected BMK cells at 50 h.p.i. Arrows indicate bands corresponding tomiRNAs. Note predominant band detected by all three probesmigrating at ∼65 nucleotides corresponds to
the pre-miRNA. Bottom panel shows pre-transferred, low molecular weight RNAs stained with ethidium bromide as a loading control (B) Time course of pre-miRNA/miRNA
accumulation (hybridized with 5 ′ probe).
160 C.S. Sullivan et al. / Virology 387 (2009) 157–167and Basilico, 1982) (Fig. 3B, right panel). To map these cleavage
fragment with single nucleotide precision, we performed 5′ RACE
analysis using a modiﬁed protocol designed to enrich for sequencing
of siRNA-like cleavage fragments. We sequenced 10 amplicons and all
10mapped a 5′ cleavage fragment to themiddle of a predictedmiRNA
region (Figs. 3A and C). 9 of the 10 amplicons mapped to a position
within the predicted 5p miRNA, and 1 mapped to the 3p miRNA
region. Combined with the results of Fenton and Basillico, our data
suggest that miRNAs generated from each arm of the PyV pre-miRNA
are active (albeit to varying degrees) at generating speciﬁc cleavage
of the early RNAs.
We next asked whether the PyV miRNA-mediated cleavage of
the early RNAs results in a decrease in early protein levels. We
designed 2′-O-methylated antisense inhibitors to either the 5p or
3p PyV miRNAs. We then transfected the inhibitors at two different
times post- infection and assayed for early proteins levels by
immunoblot analysis. Transfection of the 5′ miRNA inhibitor (5′ AS)
had a modest but reproducible effect of increasing all three early
protein levels (Fig. 4). Transfection of the 3p miRNA inhibitor (3′
AS) had signiﬁcantly less of an effect (almost to negative control
levels), and transfecting a pooled combination of 1/2 the concen-
tration of both inhibitors (Both) had an intermediate effect.
Importantly, transfection of an irrelevant negative control oligonu-
cleotide or transfection reagent alone had no effect on early protein
levels (Neg. 1 and Neg. 2). These results are consistent with the
data of Fig. 3B, which suggested that the 5p miRNA is the major
species active in cleavage of PyV early RNA, the mRNA encoding the
viral T antigens.
Characterization of a dl1013, a PyV miRNA mutant virus
Next, we surveyed the literature to identify candidate PyV mu-
tants that fail to express the pre-miRNA/miRNAs. A deletion mu-
tant dl1013 (Magnusson and Berg, 1979) was the top candidate to
emerge because it met the following criteria: (1) it is a small
deletion (21 nucleotides) mapping to the middle of the pre-miRNA
(Fig. 5A), (2) the deletion results in in-frame deletions in MT and LT
(3) it is viable in cultured cells and (4) it transforms cells in culturewith normal efﬁciency. These ﬁndings suggest that this mutation is
not compromising the functionality of MT and LT. Thus, dl1013 was
a prime candidate for a mutation that would disrupt pre-miRNA/
miRNA processing while having no discernable effects on early
protein function.
As a ﬁrst step in characterizing the effects of this deletion, we
created an isogenic mutant andwildtype pair by introducing the 21 bp
deletion of dl1013 into the standard wild type laboratory strain PTA.
We then compared these strains for pre-miRNA/miRNA production.
Cells were infected with PTA-dl1013 or PTA and Northern blot analysis
performed on RNA harvested at various times post-infection (Fig. 5B).
This revealed that in PTA-dl1013 no speciﬁc bands were detected
migrating in the pre-miRNA or miRNA size range, even at the latest
times post-infection (when the pre-miRNA and miRNA are readily
detectable in wildtype-infected cells). We note that by 72 hpi, there is
substantial accumulation of heterogeneous and seemingly aberrant
RNA species in PTA-dl1013-infected cells; we speculate that these may
result from abortive processing of transcripts arising from the deletion
mutation. However, these transcripts lack any features of pre-miRNAs
or miRNAs and it is doubtful that they can play analogous functional
roles.
We then performed immunoblot analysis to examine the effects of
the mutation on early protein production. As expected, we observed a
reproducible increase in early protein LT and MT protein levels at late
times post-infection in the mutant compared to wildtype PyV (Fig.
5C). Small T accumulationwas also augmented by 50 hpi (Fig 5C), but
the effects of themutation on ST levels were not as large as those on LT
and MT. The reason for the differential effects on the three early
proteins is unclear and may reﬂect the non-linear limitations of
western blot analysis, or the differences in abundance or timing of
expression of the early transcripts. However, taken together with our
antisense miRNA inhibitor studies (Fig. 4), these results demonstrate
that the PyV miRNAs play some role in regulating the early protein
levels.
No replication defect was noted in the original dl1013 isolate
(Magnusson et al., 1981). Similarly, PTA-dl1013 in our hands grew to
comparable titer and showed no difference in the size or time of
appearance of plaques compared to PTA. (Fig. 5D). The original dl1013
Fig. 3. 5′ RACE analysis identiﬁes miRNA-mediate cleavage sites. (A) Map of predicted cleavage fragments if the PyV 5p and 3p miRNAs are active at directing cleavage of the early
mRNAs. Probes used in Northern blots analysis are shown as green rectangles. Note: themap is not drawn to scale. (B) Northern blot analysis for earlymRNAs and cleavage fragments.
Polyadenylated-enriched RNAwas probedwith oligonucleotide probes and visualized via phosphorimaging. The panel on the left depicts the blot probedwith the 5′ probe. The panel
on the left is the same blot that was stripped and re-probed with the 3′ probe. The grey arrow indicates the additional band detected only with the 3′ probe. (C) 5′ rapid ampliﬁcation
of cDNA ends (RACE) was employed using a protocol modiﬁed to enrich for cleavage fragments. Polyadenylated-enriched RNA was ligated to a linker, followed by reverse
transcription and nested PCR tomap the 5′ ends of early mRNA fragments in the vicinity of the pre-miRNA. Arrows indicate the position of mapped cleavage fragments. The numbers
above the arrows indicate that 9 of 10 amplicons sequenced map antisense to the middle of the putative 5p miRNA and 1 of 10 amplicons sequenced map antisense to the middle of
the putative 3p miRNA. The top line shows the top DNA strand, 5′ to 3′ in the early orientation. Below that is the predicted sequence of each miRNA (3′to 5′). A cartoon showing how
the nucleotides correspond to the stem (3p, blue box, 5p red box) or loop (black dots) portion of the pre-miRNA is shown at the bottom.
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temperature (Magnusson et al., 1981). We observed normal trans-
forming ability of PTA-dl1013 using F-111 established rat ﬁbroblastsFig. 4. Immunoblot analysis shows inhibition of PyV miRNAs increases early protein levels. P
Shown are representativewestern blots for LT, MT, sT, VP1 aswell as two different loading con
and ST (monoclonal antibody F4), then it was stripped and re-probed with antibody that re
band with the F4 antibody, the bottom loading control corresponds Coomassie blue-stainedassayed by growth in soft agar (Fig 5D). These results indicate that the
PyV miRNAs are not essential for virus replication or cell transforma-
tion in vitro.rotein was harvested at various times post-infection and probed with relevant antibody.
trols. Themembranewas initially probed for LT (monoclonal antibody 762), then forMT
cognized PyV VP1. The top loading control corresponds to a non-speciﬁc, cross-reacting
high molecular weight proteins after transfer to the PVDF membrane.
Fig. 5. Characterization of mutant PTA-dl1013. (A) Transcripts and amino acids of LT corresponding to the region of the early transcripts that is complimentary to the pre-miRNA
(depicted with an arrow). The region in red identiﬁes the nucleotides and LT amino acids deleted in PTA-dl1013. (B) Northern blot, probed for the 5pmiRNAwas conducted as shown
in Fig. 2. Arrows indicate bands corresponding to the pre-miRNA andmiRNA that not detectable inwildtype but notmutant PTA-dl1013-infected cells. RNAwas harvested at 24, 48, or
72 hoi from PTA-dl1013-infected BMK cells or 40 h.p.i. fromwildtype infected cells. M, mock infected. (C) Immunoblot analysis shows increased levels of LT and MT in PTA-dl1013-
infected cells. BMK cells were infected with the wildtype strain PTA (P) or the miRNA mutant virus (PTA-dl1013, (13)) at an M.O.I. of 1 and immunoblot analysis was performed for
large T antigen (LT), middles T antigen (MT), small T antigen (sT), VP1 or the load control protein GAPDH. (D) PTA-dl1013 transforms cultured cells as well as wildtype virus. Viral
titers were determined by infecting UC1B cells at various dilutions, and the plaques arisen in soft-agar medium were counted. The ability of PTA-dl1013 to transform cultured cells
wasmeasured. by infecting rat ﬁbroblast F111with either PTA or PTA-dl1013 at M.O.I. of 0.5, 2.5 and 10. After 16 h post infection, the infected cells weremixedwith soft-agar medium
and immediately plated in 60 mm plates. The transformed cells were counted af ter 2 weeks.
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PyV infection of mice is a well-characterized animal model of viral
infection. We took advantage of this established model and infected
mice to look for a possible role for the PyV miRNAs. Adult C57BL/6
mice were subcutaneously (s.c.) inoculated with 1×105 PFU of either
wildtype or dl1013 virus, and the spleens and kidneys were harvested
at 3, 7, or 34 days post-infection.
We have previously hypothesized that autoregulation of the
early protein levels by the SV40 miRNAs may play a role in evading
the CTL response in vivo (Sullivan et al., 2005). Because there are
notable similarities between the PyV and SV40 pre-miRNAs (e.g.
both are made late during infection, and both make two different
miRNAs that direct cleavage of the early RNAs), we tested whether
dl1013 has an altered PyV-speciﬁc CD8 T cell response in vivo. In
order to visualize the frequency of PyV-speciﬁc CD8 T cells, we
stained cells with a tetramer consisting of Db molecules bound to
the dominant MHC Class-I restricted epitope from PyV (LT359–368)
(Kemball et al., 2005). The magnitude of the Db-LT359 response wascomparable between wildtype and dl1013-infected animals during
both the acute and persistent phases of PyV infection (Fig. 6A).
Furthermore, no differences were observed in secretion of IFNγ, a
cytokine used to assess the functionality of T cells stimulated with
the LT359 peptide at either 7 or 34 days post infection (Fig. 6B).
Within the spleen and kidney, no major differences in viral
clearance were observed (Fig. 6C). To see if a reduced viral infection
would reveal differences in viral clearance or anti-viral CD8 T cell
responses, we administered a smaller viral inoculum (1×103 PFU)
of PTA or PTA-dl1013 to adult mice; however, Db LT359 CD8 T cell
responses at day 10 post infection in the spleen and lung remained
similar between the two groups, as was splenic viral DNA load (data
not shown). To more closely approximate natural PyV exposure, we
investigated whether neonates might exhibit differences in viral
clearance rates. Neonatal mice were infected with 1×103 PFU of
each virus within 24 h after birth, and spleens and kidneys were
removed at 1, 7, and 14 days post infection. As shown in Fig. 7, no
signiﬁcant differences were noted in either the spleen or kidney at
any of these timepoints.
Fig. 6. Deletion of microRNA sequences does not signiﬁcantly alter the magnitude of the acute or memory LT359-speciﬁc CD8 T cell response or clearance of virus in adult mice.
C57BL/6 mice (n=4)were infected s.c. with 105 PFU of either PTA PyV or PTA-dl1013 virus. The spleens and kidneys were removed and processed on d7 or d34. Absolute numbers of
Db LT359-speciﬁc CD8 T cells in the spleen are depicted in (A), while the acute and memory responses are shown in (B). Spleen and kidney tissue samples were processed at the
indicated timepoints and viral genome copy numbers were quantiﬁed using Taqman real-time PCR (C).
163C.S. Sullivan et al. / Virology 387 (2009) 157–167These results suggest that under the experimental conditions we
employed, the PyV miRNAs have little effect on the induction of the
CD8 Tcell response to LT in vivo. Although the overall similarity of viral
titers in the mice argues against a large and sustained effect in this
regard, the possibility of a more modest effect at lower target-effector
ratios cannot be excluded.
Discussion
Viral-encoded miRNAs have garnered much interest, in part, as
possible targets for therapeutic intervention. Viral miRNAs have been
described for several members of the Herpesvirus and Polyomavirus
families, and possibly HIV (a lentivirus) (Cullen, 2006; Grey et al.,
2008; Nair and Zavolan, 2006; Omoto and Fujii, 2005; Omoto et al.,
2004; Pfeffer and Voinnet, 2006; Samols and Renne, 2006; Sarnow
et al., 2006; Sullivan and Ganem, 2005b). In addition, a small per-
centage of the adenovirus VA RNAs made during infection is pro-
cessed into RISC without Drosha processing (Andersson et al., 2005;
Aparicio et al., 2006; Lu and Cullen, 2004; Xu et al., 2007). Thus, VA
RNAs can be considered a pre-miRNA that gives rise to miRNAs
through an atypical route of processing. Target mRNAs for some viral
miRNAs have been described, but detailed biological functions have
been ascribed to only a minority of such miRNAs, and even fewer
studies have addressed the roles viral miRNA functions in the intact
animal host.In this report we show that the well-characterized model virus,
PyV encodes a pre-miRNA. We have previously shown that SV40, a
monkey polyomavirus encodes a pre-miRNA with several distinct
features: (1) the SV40 pre-miRNA is made at robust levels late in the
infectious cycle, (2) it is processed into two active miRNAs, one from
each arm of the hairpin precursor, and (3) both SV40 miRNAs are
active at directing the cleavage of the same substrates — the early
mRNAs. The PyV pre-miRNA shares all of these characteristics with its
cognate pre-miRNA in SV40 (Figs. 2 and 3). However, there are notable
differences as well: no sequence similarity is detected between the
SV40 and PyV pre-miRNAs and they are encoded in different regions
of the genome (although both are complementary to the early
mRNAs). Additionally, we note that although the viral RNA targets of
these miRNAs are well-documented, this in no way excludes the
possibility that the polyomaviral miRNAs might also target host
transcripts.
Interestingly, the PyV miRNAs appear to be dispensable for PyV
infection after experimental inoculation of either cultured cells or
intact mice. PTA-dl1013 fails to make the PyV pre-miRNA or miRNAs
yet replicates and transforms well in culture and replicates and
spreads efﬁciently in the mouse (Fig. 6C). Furthermore, no
differences are observed in the CD8 T cell response to LT in mice
that are sacriﬁced at 7 or 34 days post infection dpi. How can one
account for the fact that the PyV miRNAs are not required in
experimental murine infection? While it is formally possible that
Fig. 7. Infection of neonates with either PTA or PTA-dl1013 does not yield signiﬁcant
differences in viral clearance in neonatal mice. Neonatal mice were infected sub-
cutaneously (s.c.) with 103 PFU of virus and sacriﬁced at the indicated timepoints.
Spleen and kidney tissue samples were processed and viral genome copy numbers were
quantiﬁed using Taqman real-time PCR.
164 C.S. Sullivan et al. / Virology 387 (2009) 157–167the PyV pre-miRNA serves no important function in PyV biology,
the conservation of abundantly expressed pre-miRNA structures
with perfect homology to early mRNAs in multiple members of the
Polyomaviridae makes this proposal highly unlikely. We note in this
connection that in several other viruses (e.g. HSV and HCMV), a
large fraction of the genome can be regarded as dispensable by
similar laboratory criteria, yet many of these genes play critical roles
in the biology of natural infection (Mocarski et al., 2007; Roizman
et al., 2007).
Clearly, whatever function these miRNAs serve is not required for
infection as it is commonly studied in experimental settings. However,
laboratory PyV infection bears little resemblance to authentic PyV
infection as it occurs in the wild — and it is the latter type of infection
that has shaped the evolution of the PyV genome. Laboratory
protocols for infection have been optimized for experimental
convenience— especially for high efﬁciency of infection and potential
for tumorigenesis. These considerations favor parenteral exposure
with large amounts of virus. However, in nature PyV is transmitted by
mucosal exposure of the upper respiratory tract to very low levels
of virus — conditions which might make the virus substantially more
vulnerable to attack by either innate immune factors or CTLs.
(Moreover, typically such transmission events occur among neonates
or juveniles, rather than the adult animals we employed for much of
the study). Under natural conditions, even a slight decrement in
susceptibility to such attack (as described in vitro for the SV40miRNAs
(Sullivan and Ganem, 2005b)) could confer a substantial selectiveadvantage. Our short-term experimental inoculation protocol also
does not examine another aspect of infection — the persistent or
intermittent shedding of virus in the urine (which is the presumed
source of the virus that is spread between individuals in the
population). If the miRNAs promoted even a modest extension of
such shedding, this too could have important epidemiologic con-
sequences for the virus and be positively selected during viral evolu-
tion. Future studies of polyomavirus miRNA biology will need to focus
on these and other subtler phenotypes affecting the innate immune
response, viral persistence in individuals, and transmission in the
population, rather than on effects on single-cycle infection in vitro or
short-term replication in vivo.
Materials and methods
Cells and virus strains
Baby mouse kidney (BMK), UC1B and NIH 3T3 cells were grown
in DMEM with 10% newborn calf serum and used for viral infection
or transfection. Mouse polyoma virus strains PTA and PTA-dl1013
were used in this study. PTA-dl1013, a PTA version of dl1013 (a
derivative of the strain A2) was created by using polymerase chain
reaction (PCR) and site-directed mutagenesis methods. Brieﬂy, a
21 bp corresponding to the dl1013-deleted region was targeted for
deletion by PCR using the QuikChange site-directed mutagenesis kit
(Stratagene), a primer set (5′-GGAGTACATGCCAATGGAACCGGAGG-
AACAAGTACCCC/5′-GGGGTACTTGTTCCTCCGGTTCCATTGGCATG-
TACTCC) and PTA-pBluescript plasmid DNA as a template. The
ampliﬁed circular DNA was transformed into bacterial cells, and the
structure of the plasmid DNA from each bacterial colony was
determined by sequencing. The plasmid having the targeted deletion
was transfected into NIH 3T3 cells, and the viruses were harvested at
9 days post transfection. Then the mutant virus PTA-dl1013 was
plaque puriﬁed on UC1B cells, and its structure was conﬁrmed again
by sequencing.
Immunoblot analysis for Polyoma proteins
For the studies performed in Fig. 4, the methodology for immu-
noblots was performed as previously described (Sullivan and Ganem,
2005a). NIH 3T3 cell were infected with an MOI of 10 with the
wildtype (PyV PTA) strain. 20 μg of total protein was run on a dena-
turing SDS polyacrylamide gel. Proteins were then electroblotted
onto PVDF membranes (Millipore) and were blocked in a solution of
TBST and 5% condensed milk (Carnation). All probings were carried
out in TBST, 0.5% TBST. MT was probed with monoclonal antibody 762
(obtained from Steve Dilworth, Imperial College, London). For sT and
LT, monoclonal antibody F4 (Pallas et al., 1986) that recognizes all
three T antigens was used. Initially blots were probed with a 1:
25,000 dilution of Ab 762 over night at 4 °C, were washed in TBST and
probed with HRP-conjugated goat anti-mouse secondary antibody
(Sigma) at a 1: 50,000 dilution. Then blots were probed with hybri-
doma supernatant from cells expressing the monoclonal Ab F4, at a
dilution 1:125 for 2 h. Blots were stripped with commercial stripping
reagent according to manufacturer's suggestions (Pierce/Thermo
Scientiﬁc) and re-probed with anti- VP-1 antibody (obtained from
Bob Garcea, University of Colorado Health Science Center) at
1:12,000 dilution.
BMK cells were infected at anM.O.I. of 1, and lysates of the infected
cells were prepared in PBS with 1% NP40 and protease inhibitor
cocktail (Roche) at indicated times post infection. Collected samples
were subjected to gel electrophoresis using 4–20% gradient Tris–HCl
gels (Invitrogen), and was followed by transfer to a nitrocellulose
membrane. This membrane was blocked overnight or for 2 h in PBST
buffer (PBS with 0.1% Tween 20) containing 5% non-fat dry milk, and
then probed with antibodies against T antigens (F4), VP1 and GAPDH
165C.S. Sullivan et al. / Virology 387 (2009) 157–167(Calbiochem; 1:90,000 dilution). After washing in 20 ml of PBST ﬁve
times at room temperature, the membrane was incubated with Alexa
ﬂuor 680 anti-mouse IgG and 800 anti-rabbit IgG antibodies (1:15,000
dilution; LI-COR Biosciences, Lincoln, NE) in PBST containing 5% non-
fat milk solids for 45 min at room temperature and washed in PBST
ﬁve times. The membrane was scanned using Odyssey infrared
imaging system (LI-COR Biosciences).
Antisense miRNA inhibition studies
Cells were infected at an M.O.I. of 1, and were transfected twice,
once at 5 h.p.i., and again and 24 h.p.i. with an irrelevant 2′-O-
methylated oligonucleotide, an anti-5p miRNA 2′-O-methylated
oligonucleotide, an anti-3p miRNA 2′-O-methylated oligonucleotide,
or a combination of the anti-5p and anti-3p 2′-O-methylated oligo-
nucleotide. Cells were transfected with 30 nM of total oligonucleotide
using Lipofectamine 2000 (Invitrogen) according to manufacturer's
instructions.





Northern blot analysis for early cleavage fragments
Total RNA was harvested utilizing RNABee (Tel-Test Laboratories,
Friendswood Texas). The samples were enriched for polyadenylated
RNA using the Oligotex mRNA mini kit (Qiagen) according to the
manufacturer's protocol. Polyadenylated-enriched RNA, obtained from
approximately 30 μg/sample of total RNA, was loaded into each well.
Samples were electrophoresed through a 5% polyacrylamide (acryla-
mide:bis, 29:1, BioRad), 0.5× TBE, urea denaturing gel for approxi-
mately 9 h at 300 V. A large, wire-bound transfer apparatus (BioRad)
was used to electroblot transfer the gels to Hybond N+ membrane
(Amersham) in 0.5× TBE for 1.5 h as follows: 30 V for 1 h, 40 V for an
additional 30 min. Blotted membranes were UV crosslinked and
allowed to dry overnight at room temperature. Membranes were
hybridized with 10 pmol of radiolabeled oligonucleotide probes (end-
labeled with T4 polynucleotide kinase) in ExpressHyb hybridization
solution (Clontech) at the temperatures listed below. Blots were
washed at room temperature ∼4 times with 2× SSC, 0.05% SDS
followed by 2 washes with 0.1× SSC, 0.1% SDS. Blots were exposed
overnight to a Phosphorimager screen (Kodak).
Probes used:
PY_5′Probe: TAGGTCGGGTTGCTCAGAAGAC (53 °C hybridization
temperature)
PY_3′Probe: GAGGCCTGGCTTATTTTCTGTT (48 °C hybridization
temperature)
5′ RACE analysis of early cleavage fragments
A modiﬁed version of Llave et al. was used (Llave et al., 2002). The
RLM RACE kit (Ambion) was used according to manufacturer's direc-
tions, except the calf intestine alkaline phosphatase and tobacco acid
pyrophosphatase steps were omitted so as to enrich for up-capped
potential miRNA-mediated cleavage fragments. Amplicons were
cloned into the TOPO TA cloning kit (Invitrogen) and plasmid DNA
was harvested and sequenced from 10 different colonies previously
screened to have an insert.
The primers used for this study:
PyV-speciﬁc outer primer: AGGCTTGGTGACTGCCTTACACAT
PyV-speciﬁc inner primer: GGCATTTGAATTCGGGCCTGAACTSmall RNA Northern blots
miRNAs were detected as previously described (Grundhoff et al.,
2006; Sullivan and Grundhoff, 2007). Brieﬂy, BMK cells were infected
at anM.O.I. of 10, and total RNAwas extractedwith RNABee (TEL-TEST,
INC., Friendswood, TX) at various times post-infection. Fifteen micro-
grams of total RNAwere run on a urea denaturing 15% polyacrylamide
gels and electroblot transferred to Hybond N+ membrane (Amer-
sham). Blots were probed at 38.5 °C in Expresshyb (Clontech) hybri-
dization solution and washed 4 times with room temperature 2× SSC,
0.1% SDS. T4 PNK (USB)-labeled oligonucleotides were used as probes.




In vitro transformation assays
F111 rat embryo ﬁbroblasts were infected with WT PTA or PTA-
dl1013 atM.O.I. of 0.5, 2.5 and 10. After 16 h post infection, the infected
cells were trypsinized, collected by centrifugation, resuspended in
soft-agar medium and immediately plated in 60 mm plates as (Raptis
et al., 1985). The transformed cells were counted after 14 days.
Mice
C57BL/6J mice used for neonatal infection were purchased from
the Jackson Laboratory (Bar Harbor, Maine). They were kept in the SPF
barrier facility at Harvard Medical School prior to use. C57BL/6NCr
female mice were purchased from the Frederick Cancer Research and
Development Center of the National Cancer Institute (Frederick, MD).
Mice were housed and bred in accordance with the guidelines of the
Institutional Animal Care and Use Committee, and the Department of
Animal Resources at Emory University.
Virus inoculations. Each mouse was inoculated s.c. in the hind
footpads with 1×103 or 1×105 PFU of virus. Mice were infected at 6–
12 weeks of age. Neonatal mice were infected s.c. with 1×103 PFU
within 24 h after birth.
Peptides and intracellular IFN-γ staining
LT359–368C7Abu peptide was synthesized and stored as pre-
viously described (Kemball et al., 2005). Cells were stimulated directly
ex vivo with 1 µM peptide and stained for CD8α and IFN-γ as des-
cribed (Kemball et al., 2005).
Flow cytometry
Cells were stained in PBS containing 2% FBS and 0.1% sodium azide
(FACS buffer) for 40 min at room temperature (tetramer staining) or
according to the manufacturer's instructions for intracellular staining
(BD Biosciences). Samples were washed twice in FACS buffer. Samples
were immediately acquired on a FACSCalibur (BD Biosciences). Cells
were stained with allophycocyanin-conjugated tetramer. Anti-CD8α
and IFN-γ antibodies were purchased from BD Pharmingen. Datawere
analyzed using FloJo software (Tree Star).
Quantiﬁcation of PyV genomes
DNA isolation and Taqman PCR were performed as described
(Kemball et al., 2005). The PyV DNA quantity is expressed in genome
copies per milligram of tissue and is calculated based on a standard
curve of known PyV genome copy number vs threshold cycle of
detection. The detection limit with this assay is 10 copies of genomic
viral DNA.
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While this work was under review, we discovered that the recently
identiﬁed humanpolyomavirus—Merkel Cell Polyomavirus, encodes a
pre-miRNA in a similar region of the genome as the muPyV pre-
miRNA described here (Seo et al., 2009).
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